Clinical approach and utilizing liquid biopsies to interrogate suspected acquired resistance to PD-1 blockade
PD-1 blockade is now routine for nearly all patients with non-small lung cancer. Acquired resistance to PD-1 blockade – defined generally as an initial response followed later by progression [1-3] is a common yet poorly understood concept. A key clinical challenge to insight has been a lack of stand...
Saved in:
| Main Authors: | Dilanka Lakshan De Silva, Jia Luo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Future Science OA |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.2144/fsoa-2023-0010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Exosomal PD-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy
by: Tetsuichi Kansha, et al.
Published: (2025-07-01) -
Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer
by: Haowei Wang, et al.
Published: (2025-02-01) -
Concurrent immune checkpoint blockade for enhanced cancer immunotherapy utilizing engineered hybrid nanovesicles
by: Yuxuan Liu, et al.
Published: (2024-11-01) -
Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies
by: Peng Gao, et al.
Published: (2025-08-01) -
Statin Drugs Are Associated With Response to Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer
by: Tyler J. Kristoff, et al.
Published: (2025-03-01)